Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound
Abstract The anticancer activity of bortezomib (BTZ) has been increasingly studied in a number of indications and promising results for the use of this treatment have been shown in neuroblastoma. As BTZ treatment is usually administered in cycles, the development of resistance and side effects in pa...
Guardado en:
Autores principales: | Karolina Łuczkowska, Katarzyna Ewa Sokolowska, Olga Taryma-Lesniak, Krzysztof Pastuszak, Anna Supernat, Jonas Bybjerg-Grauholm, Lise Lotte Hansen, Edyta Paczkowska, Tomasz K. Wojdacz, Bogusław Machaliński |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f1af3d190e0e46aab864a91cdf1eba2b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
por: Peihua Luo, et al.
Publicado: (2011) -
Adjuvant Lineage-Negative Cell Therapy as a Potential Silencer of the Complement-Mediated Immune System in ALS Patients
por: Anna Sobuś, et al.
Publicado: (2021) -
Bortezomib in autoimmune hemolytic anemia and beyond
por: Raffaella Pasquale, et al.
Publicado: (2021) -
Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.
por: Michele Tanturli, et al.
Publicado: (2011) -
Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells
por: Shu Wang, et al.
Publicado: (2017)